Trends in benzodiazepine anxiolytics and z-hypnotics use among French drivers involved in road traffic crashes from 2005 to 2015: a responsibility case-control study

Ludivine Orriols,Emmanuel Lagarde,Blandine Gadegbeku,Gwladys Nadia Gbaguidi,Benjamin Contrand

doi:10.1186/s40621-019-0209-8

Abstract

BackgroundIn France, benzodiazepine anxiolytics and z-hypnotics (zolpidem and zopiclone) account for the largest share of road traffic crash risk attributable to exposure to prescription drugs. The aim of this study was to monitor the evolution of the use of these prescription drugs and their association with crash risk over a period that began before the implementation of a color-graded pictogram system printed on prescription drug boxes.MethodsData from three French national databases were extracted and linked: the national health care insurance database, police reports, and the national police database of injurious crashes. Drivers involved in an injurious crash in France, from July 2005 to December 2015, and identified by their national identifier were included. The association with crash risk was estimated using a responsibility analysis comparing the use of benzodiazepines and z-hypnotics among drivers responsible or not for the crash.ResultsA total of 97,936 responsible and 103,522 non-responsible drivers involved in an injurious crash were included. The proportion of drivers exposed to benzodiazepine anxiolytics or z-hypnotics remained stable among responsible and non-responsible drivers. Among controls from the general population, the proportion of exposed individuals tended to increase. The association with crash risk remained almost constant over the study period. The odds-ratio for benzodiazepines ranged between 1.42 [1.24–1.62] at the beginning of the study period and 1.27 [1.09–1.47] at the end.ConclusionGiven the increase in exposure in the control group from the general population, the stability of exposure for responsible and non-responsible drivers can be interpreted as a relative effectiveness of the pictogram on driver exposure levels. On the other hand, while the intrinsic effect of a prescription drug cannot be modified, a decrease in risk could have been expected if drivers adapted their behavior as promoted by the pictogram. Our results therefore suggest that no significant change occurred in driving behaviors or consumption patterns.

Highlights

IntroductionIn France, benzodiazepine anxiolytics and z-hypnotics (zolpidem and zopiclone) account for the largest share of road traffic crash risk attributable to exposure to prescription drugs
In France, benzodiazepine anxiolytics and z-hypnotics account for the largest share of road traffic crash risk attributable to exposure to prescription drugs
The discrepancy between the number of records in the injurious crashes (IC) and in the police reports (PR) databases is explained by the fact that a small proportion of the reports were used for ongoing legal investigations and were unavailable. 59,915 NIDs were excluded because they were other type of road users

Summary

Introduction

In France, benzodiazepine anxiolytics and z-hypnotics (zolpidem and zopiclone) account for the largest share of road traffic crash risk attributable to exposure to prescription drugs. 5143 of the code of public Health on the adoption of a pictogram on the packaging of certain drugs and products), n.d.) This pictogram was printed on almost one-third of the drug boxes, some of which presented very high risks to driving while others only required a warning. This system did not allow this important distinction to be made In response to these limitations, the French National Agency for Medicines and Health Products Safety decided in 2003, to implement a standardized classification of prescription drugs according to four levels of impaired driving, from level 0 (no or negligible risk) to level 3 (major risk) with three corresponding pictograms for the levels 1, 2 and 3 (Fig. 1), replacing the unique pictogram Given that consumption levels of psychotropic prescription drugs are likely to change rapidly, among drivers whose average age is increasing, it seems necessary to continue to monitor the level of exposure to prescription drugs and the resulting risk of road traffic crashes

Objectives

Methods

Results

Discussion

Conclusion